JP2018502583A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502583A5
JP2018502583A5 JP2017536779A JP2017536779A JP2018502583A5 JP 2018502583 A5 JP2018502583 A5 JP 2018502583A5 JP 2017536779 A JP2017536779 A JP 2017536779A JP 2017536779 A JP2017536779 A JP 2017536779A JP 2018502583 A5 JP2018502583 A5 JP 2018502583A5
Authority
JP
Japan
Prior art keywords
variant
gene
polynucleotide
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502583A (ja
JP6868560B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013109 external-priority patent/WO2016115177A1/en
Publication of JP2018502583A publication Critical patent/JP2018502583A/ja
Publication of JP2018502583A5 publication Critical patent/JP2018502583A5/ja
Application granted granted Critical
Publication of JP6868560B2 publication Critical patent/JP6868560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536779A 2015-01-12 2016-01-12 修飾された肝炎転写後調節エレメント Active JP6868560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102569P 2015-01-12 2015-01-12
US62/102,569 2015-01-12
PCT/US2016/013109 WO2016115177A1 (en) 2015-01-12 2016-01-12 Modified hepatitis post-transcriptional regulatory elements

Publications (3)

Publication Number Publication Date
JP2018502583A JP2018502583A (ja) 2018-02-01
JP2018502583A5 true JP2018502583A5 (enExample) 2019-02-21
JP6868560B2 JP6868560B2 (ja) 2021-05-12

Family

ID=55310922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536779A Active JP6868560B2 (ja) 2015-01-12 2016-01-12 修飾された肝炎転写後調節エレメント

Country Status (17)

Country Link
US (1) US10363269B2 (enExample)
EP (1) EP3245292B1 (enExample)
JP (1) JP6868560B2 (enExample)
KR (1) KR102554374B1 (enExample)
CN (1) CN107429260B (enExample)
AU (1) AU2016206868B2 (enExample)
BR (1) BR112017014917A2 (enExample)
CA (1) CA2973483A1 (enExample)
ES (1) ES2877367T3 (enExample)
IL (1) IL253399B2 (enExample)
MA (1) MA41346A (enExample)
MX (1) MX391694B (enExample)
MY (1) MY187559A (enExample)
RU (1) RU2734594C2 (enExample)
SA (1) SA517381912B1 (enExample)
SG (1) SG11201705692SA (enExample)
WO (1) WO2016115177A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2019028273A1 (en) * 2017-08-02 2019-02-07 Dna2.0, Inc. Dba Atum DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
US20230038502A1 (en) 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質-金属水酸化物錯体およびその方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
WO2021081280A1 (en) 2019-10-23 2021-04-29 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for generating engineered memory-like nk cells and compositions thereof
DE102020111571A1 (de) * 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023523314A (ja) 2020-04-27 2023-06-02 ジュノー セラピューティクス インコーポレイテッド ポリエチレンイミン-デオキシリボ核酸複合体のサイズおよび活性の安定化
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021252952A1 (en) * 2020-06-11 2021-12-16 Sangamo Therapeutics, Inc. Methods and compositions for expressing phenylalanine hydroxylase
MX2023000124A (es) * 2020-06-30 2023-03-08 Univ Court Univ Of Edinburgh Sistema de expresion de transgenes.
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
KR20220035693A (ko) * 2020-09-14 2022-03-22 주식회사 제너로스 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터
CA3197320A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Dlx2 vector
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
US20230049217A1 (en) * 2021-05-21 2023-02-16 Novartis Ag Compositions and methods for enhancing visual function
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
AU2022379949A1 (en) * 2021-11-04 2024-05-02 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2024010916A1 (en) 2022-07-07 2024-01-11 Science Corporation Neural interface device
EP4598572A1 (en) * 2022-10-04 2025-08-13 Emergent Product Development Gaithersburg Inc. Novel vsv virus formulations
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2026003067A1 (en) * 2024-06-25 2026-01-02 Asgard Therapeutics Ab Transcription factors and reprogramming modulators for reprogramming cells to cdc1 cells, compositions and methods thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7262049B2 (en) 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
KR20160002030A (ko) * 2014-06-30 2016-01-07 성지산업 주식회사 도플러 센서를 이용한 대상체 감지 방법 및 장치
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法

Similar Documents

Publication Publication Date Title
RU2017126975A (ru) Модифицированные посттранскрипционные регуляторные элементы вирусов гепатита
JP7846986B2 (ja) 生物学的製剤の投与のためのアルファウイルスベースのレプリコン
JP5265643B2 (ja) 免疫治療組成物調製用のレンチウイルスベクター
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
CN107531800B (zh) 用于嵌合抗原受体分子的调控表达的慢病毒载体
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
BR112020006786A2 (pt) composições e métodos para editar rna
JP7644007B2 (ja) 第ix因子を発現するレンチウイルスベクターの使用
JP2021512126A5 (enExample)
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
CN106459998A (zh) 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗
RU2015155821A (ru) Вакцины против малярии
JP2022514465A5 (enExample)
JP2024026791A (ja) 視覚機能再生剤又は視覚機能低下予防剤
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
CN120641136A (zh) 用于额颞叶痴呆的基因疗法
CN105131124A (zh) 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途
TW202227476A (zh) 編碼GJB2之重組腺相關病毒(rAAV)及其用途
KR101713407B1 (ko) 아데노바이러스 감염 및 복제가 가능한 흑색종 세포주
JP2020522249A5 (enExample)
Chiu et al. Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein
CN117003833A (zh) 肝脏特异性的腺相关病毒血清型及应用
KR20240004429A (ko) B형 간염 치료용 렌티바이러스 벡터, 렌티바이러스 입자, 및 그의 제조 방법 및 그의 용도
WO2019077164A1 (en) CROCHET FUSION PROTEIN FOR REGULATING THE CELLULAR TRAFFIC OF A TARGET PROTEIN
JP2024537797A5 (enExample)